Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University

Rhea-AI Summary

Biohaven (NYSE: BHVN) and Yale University announced that the U.S. District Court for the District of Delaware entered judgment in their favor on August 24, 2026, in trade secret misappropriation and breach of contract litigation against Avilar Therapeutics and RA Capital Management.

The judgment, entered by Judge Jennifer L. Hall, formalizes a combined $4 million award, reflecting a jury verdict on July 24, 2026. According to Biohaven, the jury found that RA Capital and Avilar willfully and maliciously misappropriated a Yale trade secret related to the "MODA" targeted protein degradation platform, and that RA Capital separately breached a 2019 confidentiality agreement with Yale.

The Court awarded $2 million to Yale for RA Capital's contract breach, and $1 million each to Yale and Biohaven for trade secret misappropriation. The MODA platform, developed by Yale professor Dr. David Spiegel, had been licensed by Biohaven for development and commercialization. The judgment is subject to potential post-trial motions.

Positive

• $4 million judgment awarded to Yale and Biohaven combined
• $1 million trade secret misappropriation award allocated to Biohaven

Negative

• Judgment remains subject to post-trial motions, creating potential legal uncertainty

Market Context

The active, effective S-3ASR, filed May 4, 2026, permits primary offerings and resales for general c...

Analysis

The active, effective S-3ASR, filed May 4, 2026, permits primary offerings and resales for general corporate purposes. That financing flexibility frames the $4 million award, while post-trial motions remain a legal risk.

Key Figures

Combined award: $4 million Contract damages: $2 million Trade-secret damages: $1 million each +3 more

6 metrics

Combined award $4 million Federal court judgment

Contract damages $2 million Awarded to Yale for breach of contract

Trade-secret damages $1 million each Awarded to Yale and Biohaven for misappropriation

Court judgment date August 24, 2026 Judgment entered following the jury verdict

Jury verdict date July 24, 2026 Jury returned its verdict

Confidentiality agreement 2019 Agreement between RA Capital and Yale

Historical Context

5 past events · Latest: Aug 10 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 10	Second-quarter earnings	Neutral	-0.3%	Pipeline progress and narrowed losses accompanied by continued quarterly net loss
Aug 06	Board appointment	Positive	+5.8%	Technology investor John Yetimoglu joined the board effective immediately
Jul 27	Trade-secret verdict	Positive	+1.3%	Federal jury awarded Yale and Biohaven combined damages totaling $4 million
Jul 20	Phase 1 clinical data	Positive	-3.8%	Early tumor reductions and responses accompanied a Regeneron clinical supply agreement
Jul 09	Leadership transitions	Negative	-7.4%	Chief Scientific Officer retired and discovery leadership responsibilities changed

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent reactions were mixed: three events aligned with their apparent sentiment, while two favorable or mixed announcements diverged.

Key Terms

trade secret misappropriation, confidentiality agreement, breach of contract

3 terms

trade secret misappropriation regulatory

"trade secret misappropriation and breach of contract litigation against Avilar"

Trade secret misappropriation is the wrongful taking, use, or disclosure of a company’s confidential information—like formulas, processes, customer lists or business plans—without permission. For investors it matters because such theft can erase a company’s competitive edge, trigger costly lawsuits, disrupt revenue streams and damage reputation, similar to a rival obtaining and selling a firm’s secret recipe.

confidentiality agreement regulatory

"entered into a confidentiality agreement with Yale in April 2019"

A confidentiality agreement is a legal promise that stops people from sharing sensitive business information — like financial plans, product designs, or deal terms — with others. For investors it matters because such agreements protect value during negotiations and due diligence, reduce the risk of leaks that can move a stock price, and give a clear basis for legal action if important information is exposed.

breach of contract regulatory

"RA Capital separately breached its 2019 confidentiality agreement with Yale"

A breach of contract is when one party fails to keep the promises spelled out in a written or verbal agreement—such as missing payments, not delivering goods or services, or violating key terms. Investors care because broken agreements can trigger lawsuits, fines, unexpected costs, loss of revenue, and damaged business relationships, much like a supplier suddenly abandoning a construction project and forcing the owner to find a costly replacement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that the U.S. District Court for the District of Delaware has entered judgment in their favor in the trade secret misappropriation and breach of contract litigation against Avilar Therapeutics, Inc. ("Avilar") and RA Capital Management GP, LLC ("RA Capital"). The judgment follows the jury's July 24, 2026 verdict and formalizes a combined $4 million award to Yale and Biohaven.

Entered by the Honorable Jennifer L. Hall, United States District Judge, the judgment reflects the jury's findings that RA Capital and Avilar willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital separately breached its 2019 confidentiality agreement with Yale. Consistent with the verdict, the Court entered judgment awarding a combined $4 million: $2 million to Yale for RA Capital's breach of contract, and $1 million each to Yale and Biohaven for trade secret misappropriation.

Biohaven was represented by K&L Gates LLP and Morris James LLP. Susman Godfrey LLP and Farnan LLP represented Yale.

Background of the Case

• Dr. David Spiegel, a professor at Yale, developed the MODA platform, a technology designed to bind and eliminate disease-causing extracellular proteins from the body, and presented it at Yale's Lifesciences Pitchfest in 2018.
• RA Capital, a healthcare-focused investment firm, subsequently entered into a confidentiality agreement with Yale in April 2019 to evaluate a potential investment in and partnership around the technology.
• Over the following months, Dr. Spiegel shared confidential and detailed technical information with RA Capital, and the parties negotiated the terms of a possible deal. Those negotiations ended without an agreement in August 2019.
• Biohaven and Yale alleged that RA Capital, together with Avilar Therapeutics, a company RA Capital helped establish later that year, used confidential information from those discussions to build a competing drug development program instead of pursuing a partnership with Yale.
• Biohaven licensed the MODA platform from Yale to develop and commercialize the technology.
• Biohaven and Yale filed suit against Avilar and RA Capital in March 2023 in the U.S. District Court for the District of Delaware, alleging trade secret misappropriation and breach of the confidentiality agreement between Yale and RA Capital. The case proceeded to a jury trial beginning July 20, 2026, and the jury returned its verdict on July 24, 2026.
• On August 24, 2026, the Court entered judgment following the jury verdict, formalizing the combined $4 million award. Following the entry of judgment, the parties may file post-trial motions, and the judgment is subject to the Court's consideration of those motions.

About Biohaven

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies for people with debilitating diseases, with a broad pipeline spanning neuroscience, immunology, and other therapeutic areas. For more information, visit biohaven.com.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "potentially", "potentially groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the litigation described above and its ultimate outcome, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the outcome of legal proceedings, including any post-trial motions, appeals, and the final amount of any award or recovery; the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact: Jennifer Porcelli
Vice President, Investor Relations, Biohaven
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741

Media Contact: Renée Soto
Founding Partner, Reevemark
renee.soto@reevemark.com
+1 (212) 433-4606

View original content to download multimedia:https://www.prnewswire.com/news-releases/federal-court-enters-judgment-confirming-ra-capital-and-avilar-therapeutics-willfully-and-maliciously-misappropriated-trade-secret-developed-at-yale-formalizing-4-million-award-to-biohaven-and-yale-university-302859834.html

SOURCE Biohaven Ltd.

FAQ

What did the August 2026 federal court judgment decide in the Biohaven (BHVN) and Yale case?

The Delaware federal court entered judgment for Biohaven and Yale, confirming a $4 million award. According to Biohaven, this reflects jury findings of trade secret misappropriation and breach of a 2019 confidentiality agreement involving Yale’s MODA protein degradation platform.

How is the $4 million award in the Biohaven (BHVN) and Yale judgment allocated?

The judgment allocates $2 million to Yale for RA Capital’s contract breach and $1 million each to Yale and Biohaven for trade secret misappropriation. According to Biohaven, this structure mirrors the jury’s July 24, 2026 verdict in Delaware.

What is Yale’s MODA targeted protein degradation platform mentioned in the Biohaven (BHVN) case?

The MODA platform is a Yale-developed technology designed to bind and eliminate disease-causing extracellular proteins. According to Biohaven, Dr. David Spiegel created MODA at Yale, and Biohaven licensed it from Yale to develop and commercialize targeted protein degradation therapies.

When did the court enter judgment in favor of Biohaven (BHVN) and Yale in the Avilar and RA Capital case?

The U.S. District Court for the District of Delaware entered judgment on August 24, 2026. According to Biohaven, this followed a four-day jury trial that began July 20, 2026, with the verdict returned on July 24, 2026.

Is the $4 million judgment for Biohaven (BHVN) and Yale against Avilar and RA Capital final?

The judgment is entered but not yet fully final, as parties may file post-trial motions. According to Biohaven, the August 24, 2026 judgment is subject to the Court’s consideration of any such motions before the case is fully concluded.

How is Biohaven (BHVN) involved with Yale’s MODA trade secret at issue in the lawsuit?

Biohaven licensed Yale’s MODA targeted protein degradation platform to develop and commercialize the technology. According to Biohaven, this licensing relationship positioned Biohaven as a plaintiff with Yale in pursuing the trade secret misappropriation and breach of contract claims in Delaware federal court.